SCHEMBL4580487

SCHEMBL4580487

CCCCCCCCCCCCCCCCCCOC(C)OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 1/20 0.48
PRKD3 O94806 1/20 0.39
PRKCG P05129 1/20 0.39
PRKCB P05771 1/20 0.39
PRKCA P17252 1/20 0.39
PRKCH P24723 1/20 0.39
PRKCI P41743 1/20 0.39
PRKCE Q02156 1/20 0.39
PRKCQ Q04759 1/20 0.39
PRKCZ Q05513 1/20 0.39
PRKCD Q05655 1/20 0.39
PRKD1 Q15139 1/20 0.39
THRB P10828 2/20 0.38
TSHR P16473 1/20 0.38
LPAR1 Q92633 9/20 0.38
LPAR3 Q9UBY5 9/20 0.38
LPAR2 Q9HBW0 6/20 0.38
LPAR6 P43657 5/20 0.38
LPAR4 Q99677 5/20 0.38
LPAR5 Q9H1C0 5/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27629301 1.00 DNM1 (0.48) DNM1PRKD3PRKCGPRKCBPRKCA
SCHEMBL3502859 1.00 DNM1 (0.48) DNM1PRKD3PRKCGPRKCBPRKCA
SCHEMBL15160848 0.98 DNM1 (0.45) DNM1PRKD3PRKCGPRKCBPRKCA
SCHEMBL441733 0.90
SCHEMBL873400 0.87 DNM1 (0.54) DNM1THRBTSHRLPAR1LPAR3
SCHEMBL16841236 0.87 DNM1 (0.54) DNM1THRBTSHRLPAR1LPAR3
SCHEMBL25509452 0.87 DNM1 (0.54) DNM1THRBTSHRLPAR1LPAR3
SCHEMBL6686359 0.87 DNM1 (0.54) DNM1THRBTSHRLPAR1LPAR3
SCHEMBL683435 0.87 HTT (0.50) DNM1PRKD3PRKCGPRKCBPRKCA
SCHEMBL28557811 0.85 DNM1 (0.50) DNM1THRBTSHRLPAR1LPAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080071084-A1 Using an alcohol in presence of copper catalyst and ligand ARCHIMICA GMBH (DE) 2008-03-20 US claimed
EP-1873136-A1 Method for manufacturing alkyl and aryl ethers Archimica GmbH (DE) 2008-01-02 EP claimed
US-20170305848-A1 SULFONIUM SALT, PHOTOACID GENERATOR, AND PHOTOSENSITIVE COMPOSITION TOKYO OHKA KOGYO CO., LTD. (JP) 2017-10-26 US disclosed
US-20170305848-A1 SULFONIUM SALT, PHOTOACID GENERATOR, AND PHOTOSENSITIVE COMPOSITION TOKYO OHKA KOGYO CO., LTD. (JP) 2017-10-26 US disclosed
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
CN-101255170-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-09-03 CN disclosed
CN-101172981-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-05-07 CN disclosed
US-20080071084-A1 Using an alcohol in presence of copper catalyst and ligand ARCHIMICA GMBH (DE) 2008-03-20 US disclosed
CN-100366624-C 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds OTSUKA PHARMA CO LTD (JP) 2008-02-06 CN disclosed
EP-1873136-A1 Method for manufacturing alkyl and aryl ethers Archimica GmbH (DE) 2008-01-02 EP disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170305848-A1 SULFONIUM SALT, PHOTOACID GENERATOR, AND PHOTOSENSITIVE COMPOSITION ARSA, SPIN1, ASIC1 DNM1 1984/4885PRKD3 1173/4885PRKCG 2983/4885
US-20080071084-A1 Using an alcohol in presence of copper catalyst and ligand NR1H3, NR1H2, ADH1A DNM1 2704/4885PRKD3 4623/4885PRKCG 4641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.